drugset / Trial / NCT02207491

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491

Phase 3 Completed 411 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%

Timeline

Start
2014-07
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Topical
Comparator Timolol Other / unclassified 0.5 % Topical